Business
Cytokinetics Announces Positive Topline Results of Redwood-HCM
Phase 2 Clinical Trial of CK-274 Demonstrated Consistent and Clinically Meaningful Reductions in Left Ventricular Outflow Tract Gradients Within Two Weeks in
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"Phase 2 Clinical Trial of CK-274 Demonstrated Consistent and Clinically Meaningful Reductions in Left Ventricular Outflow Tract Gradients Within Two Weeks in Patients with Obstructive Hypertrophic Cardiomyopathy No Treatment Interruptions or Discontinuations Due to Reduction in Left Ventricular Ejection Fraction Phase 3 Registrational Trial of CK-274 Expected to Start Before Year End Company to Host Conference Call and Webcast Today at 8:30 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2 clinical trial of CK-3773274 (CK-274), an investigational next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM). The results of REDWOOD-HCM inform dose selection and support progression of CK-274 to a planned Phase 3 registrational clinical trial which is expected to start before year end. Results from Cohorts 1 and 2 of REDWOOD-HCM demonstrated that treatment with CK-274 for 10 weeks resulted in statistically significant reductions from baseline compared to placebo in the average resting left ventricular outflow tract pressure gradient (LVOT-G) (p=0.0003, p=0.0004, Cohort 1 and Cohort 2, respectively) and the average post-Valsalva LVOT-G (p=0.001, p","length":1958,"tagName":"div"}]